Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03409614 · OUTCOME

Part 1: Duration of Response (DoR)

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer · Source last updated 2026-05-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Up to 32 months

What was measured

DoR was defined as the time from date of first documented response of CR or PR to the date of first documented progressive disease (PD) or death due to any cause, whichever occurred earlier.

Analysis population: Part 1 participants with confirmed CR or PR only. Overall number of participants analyzed = number of participants with evaluable data for the outcome measure

Groups in this outcome

Part 1: Cemiplimab + Chemotherapy

Participants received cemiplimab plus platinum-based doublet chemotherapy

Part 1: Cemiplimab+AbbrevChemo+Ipilimumab

Participants received cemiplimab plus platinum-based doublet chemotherapy and ipilimumab

Part 1: Chemotherapy

Participants received platinum-based doublet chemotherapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part 1: Cemiplimab + Chemotherapy44
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab40
Part 1: Chemotherapy30

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Part 1: Cemiplimab + Chemotherapy7.8Not reported6.213.2Not reported
Part 1: Cemiplimab+AbbrevChemo+Ipilimumab15.9Not reported8.735.1Not reported
Part 1: Chemotherapy6.2Not reported5.210.4Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        6.2
        upper Limit
        13.2
        value
        7.8
      2. group Id
        OG001
        lower Limit
        8.7
        upper Limit
        35.1
        value
        15.9
      3. group Id
        OG002
        lower Limit
        5.2
        upper Limit
        10.4
        value
        6.2
denoms
  1. counts
    1. group Id
      OG000
      value
      44
    2. group Id
      OG001
      value
      40
    3. group Id
      OG002
      value
      30
    units
    Participants
description
DoR was defined as the time from date of first documented response of CR or PR to the date of first documented progressive disease (PD) or death due to any cause, whichever occurred earlier.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants received cemiplimab plus platinum-based doublet chemotherapy
    id
    OG000
    title
    Part 1: Cemiplimab + Chemotherapy
  2. description
    Participants received cemiplimab plus platinum-based doublet chemotherapy and ipilimumab
    id
    OG001
    title
    Part 1: Cemiplimab+AbbrevChemo+Ipilimumab
  3. description
    Participants received platinum-based doublet chemotherapy
    id
    OG002
    title
    Part 1: Chemotherapy
param Type
MEDIAN
population Description
Part 1 participants with confirmed CR or PR only. Overall number of participants analyzed = number of participants with evaluable data for the outcome measure
reporting Status
POSTED
time Frame
Up to 32 months
title
Part 1: Duration of Response (DoR)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice